Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CHAT | P28329 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.38 |
| ▸ | DTYMK | P23919 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786902 | 0.95 | JAK2 (0.43) | JAK2CHATAURKANAA50EP300 | |
| SCHEMBL21786901 | 0.91 | P2RY2 (0.40) | JAK2POLB | |
| SCHEMBL21787157 | 0.88 | POLG (0.38) | JAK2POLB | |
| SCHEMBL21786899 | 0.87 | JAK2 (0.33) | JAK2 | |
| SCHEMBL21787069 | 0.86 | KRAS (0.39) | JAK2POLB | |
| SCHEMBL21787159 | 0.86 | POLB (0.42) | JAK2DTYMKPOLB | |
| SCHEMBL21786903 | 0.84 | POLG (0.35) | JAK2POLB | |
| SCHEMBL24913477 | 0.83 | ESRRA (0.34) | JAK2 | |
| SCHEMBL21786889 | 0.82 | P2RX3 (0.47) | CHATAURKANAA50EP300KAT2B | |
| SCHEMBL24913298 | 0.82 | P2RX3 (0.49) | CHATAURKAP2RX3P2RX1P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | JAK2 1849/4885CHAT 3641/4885AURKA 2339/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | JAK2 2078/4885CHAT 3414/4885AURKA 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.